Branded Legacy (OTC: BLEG), further highlighting its commitment to shareholders and future growth, today announced the final retirement of an additional 442 million common shares, bringing the total shares retired to an extraordinary 2.44 billion. The action surpasses the initial commitment and underscores Branded Legacy’s unwavering dedication to shareholder value. According to the announcement, the retirements have resulted in management now owning zero common stock, aligning the company’s leadership with the best interests of its shareholders. “We are proud to announce the retirement of an additional 442 million common shares, surpassing our initial commitment and reaffirming our dedication to shareholder value,” said CEO David Oswald. “This strategic move reflects our confidence in the company’s trajectory and our unwavering commitment to transparency and responsible corporate governance.”
To view the full press release, visit https://ibn.fm/LwiZ0
About Branded Legacy Inc.
Branded Legacy is a diversified holdings company focused on the biotech sector. With a commitment to excellence and innovation, Branded Legacy specializes in the development and marketing of cutting-edge products and services. The company’s diverse portfolio includes ventures in biotechnology, digital solutions and wellness products, all aimed at enhancing the quality of life for its customers. Branded Legacy’s strategic approach to growth involves identifying and integrating promising businesses and technologies that align with its mission to deliver sustainable, high-quality products and services. For more information, visit the company’s website at https://BrandedLegacy.com.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
